Advertisement

Topics

Kalytera Therapeutics, Inc. Company Profile

02:33 EDT 18th August 2018 | BioPortfolio

Kalytera Therapeutics, Inc. ("Kalytera") is pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs. Kalytera is focused first on developing a new class of proprietary cannabidiol ("CBD") therapeutics. CBD is a remarkable compound that has shown activity against a number of pharmacological targets. However, there are limitations associated with natural CBD, including its poor oral bioavailability. Kalytera is developing innovative CBD formulations and prodrugs in an effort to overcome these limitations, and to target specific disease sites within the body. Kalytera intends to file composition of matter and method of use patents covering its novel inventions, with the goal of limiting future competition.


News Articles [749 Associated News Articles listed on BioPortfolio]

Kalytera Therapeutics, Inc. Announces Closing of Public Offering

Kalytera Therapeutics, Inc. (TSXV:KALY) (OTCQB:KALTF) (the “Company” or “Kalytera”) is pleased to announce the closing of its previously announced public offering (the “Offering”) of units...

Kalytera Announces Pre-IND Meeting Date with FDA

Kalytera Therapeutics, Inc. (TSXV:KALY, OTCQB:KALTF) (the "Company" or "Kalytera") today announced that it will meet with the Center for Drug Evaluation and Research (“CDER”) of the U.S. Food and ...

Kalytera Completes Pre-IND Meeting with FDA

Kalytera Therapeutics, Inc. (TSXV:KALY, OTCQB:KALTF) (the "Company" or "Kalytera") today announced that it met with the United States Food & Drug Administration (“FDA”) for a pre-Investigatio...

Kalytera Reports First Quarter 2018 Financial Results

Kalytera Therapeutics, Inc. (TSXV:KALY) (OTCQB:KALTF) (the "Company" or "Kalytera") today reported financial results for the first quarter of 2018. (All dollars U.S. unless otherwise noted.) The post ...

Kalytera and Former Shareholders of Talent Biotechs Agree to Deferment of Milestone Payments

Kalytera Therapeutics, Inc. (TSXV:KALY, OTCQB:KALTF) (the "Company" or "Kalytera") today announced that it has entered into an agreement with the former shareholders of Talent Biotechs, Ltd. of Israel...

Kalytera Provides Update on its Cannabis-Based Therapy for Prevention and Treatment of GVHD

SAN FRANCISCO and TEL AVIV, Israel, June 21, 2018 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (TSX-V:KALY) and (OTCQB:KALTF) (the “Company” or “Kalytera”) today provid...

Kalytera Announces Formation of Strategic and Scientific Advisory Board to Assist with Development of Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain

Kalytera Therapeutics, Inc. (TSXV:KALY, OTCQB:KALTF) (the "Company" or "Kalytera") today announced the formation of a Strategic & Scientific Advisory Board with three key appointments: Professor...

Kalytera scraps pre-clinical programs in bone disease

Kalytera Therapeutics has announced the termination of its pre-clinical development programs in the treatment of bone disease to focus its resources on graft versus host disease (GVHD) and pain progra...

PubMed Articles [449 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development: Preclinical Research.

Clinical Trials [149 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1249 Associated Companies listed on BioPortfolio]

Kalytera Therapeutics, Inc.

Kalytera Therapeutics, Inc. ("Kalytera") is pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise,...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "Kalytera Therapeutics, Inc." on BioPortfolio

We have published hundreds of Kalytera Therapeutics, Inc. news stories on BioPortfolio along with dozens of Kalytera Therapeutics, Inc. Clinical Trials and PubMed Articles about Kalytera Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Kalytera Therapeutics, Inc. Companies in our database. You can also find out about relevant Kalytera Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Corporate Database Quicklinks



Searches Linking to this Company Record